Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:19996235rdf:typepubmed:Citationlld:pubmed
pubmed-article:19996235lifeskim:mentionsumls-concept:C0030705lld:lifeskim
pubmed-article:19996235lifeskim:mentionsumls-concept:C0036341lld:lifeskim
pubmed-article:19996235lifeskim:mentionsumls-concept:C0009079lld:lifeskim
pubmed-article:19996235lifeskim:mentionsumls-concept:C2584313lld:lifeskim
pubmed-article:19996235lifeskim:mentionsumls-concept:C0557061lld:lifeskim
pubmed-article:19996235lifeskim:mentionsumls-concept:C1552617lld:lifeskim
pubmed-article:19996235lifeskim:mentionsumls-concept:C0282443lld:lifeskim
pubmed-article:19996235pubmed:issue6lld:pubmed
pubmed-article:19996235pubmed:dateCreated2009-12-9lld:pubmed
pubmed-article:19996235pubmed:abstractTextSchizophrenia is a common neuropsychiatric disorder that is associated with an increased risk for HIV infection. Because schizophrenia may affect the ability of HIV-infected patients to adhere to their antiretroviral regimen, optimal management of their mental illness is a high priority in such individuals. However, 20% to 30% of patients with schizophrenia are refractory to first-line antipsychotics.lld:pubmed
pubmed-article:19996235pubmed:languageenglld:pubmed
pubmed-article:19996235pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:19996235pubmed:citationSubsetIMlld:pubmed
pubmed-article:19996235pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:19996235pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:19996235pubmed:statusMEDLINElld:pubmed
pubmed-article:19996235pubmed:issn1545-7206lld:pubmed
pubmed-article:19996235pubmed:authorpubmed-author:GandhiRajesh...lld:pubmed
pubmed-article:19996235pubmed:authorpubmed-author:FreudenreichO...lld:pubmed
pubmed-article:19996235pubmed:authorpubmed-author:NejadShamim...lld:pubmed
pubmed-article:19996235pubmed:issnTypeElectroniclld:pubmed
pubmed-article:19996235pubmed:volume50lld:pubmed
pubmed-article:19996235pubmed:ownerNLMlld:pubmed
pubmed-article:19996235pubmed:authorsCompleteYlld:pubmed
pubmed-article:19996235pubmed:pagination626-32lld:pubmed
pubmed-article:19996235pubmed:meshHeadingpubmed-meshheading:19996235...lld:pubmed
pubmed-article:19996235pubmed:meshHeadingpubmed-meshheading:19996235...lld:pubmed
pubmed-article:19996235pubmed:meshHeadingpubmed-meshheading:19996235...lld:pubmed
pubmed-article:19996235pubmed:meshHeadingpubmed-meshheading:19996235...lld:pubmed
pubmed-article:19996235pubmed:meshHeadingpubmed-meshheading:19996235...lld:pubmed
pubmed-article:19996235pubmed:meshHeadingpubmed-meshheading:19996235...lld:pubmed
pubmed-article:19996235pubmed:meshHeadingpubmed-meshheading:19996235...lld:pubmed
pubmed-article:19996235pubmed:meshHeadingpubmed-meshheading:19996235...lld:pubmed
pubmed-article:19996235pubmed:meshHeadingpubmed-meshheading:19996235...lld:pubmed
pubmed-article:19996235pubmed:articleTitleClozapine use in HIV-infected schizophrenia patients: a case-based discussion and review.lld:pubmed
pubmed-article:19996235pubmed:affiliationDivision of Psychiatry and Medicine, Massachusetts General Hospital, Boston, MA 02114, USA. snejad@partners.orglld:pubmed
pubmed-article:19996235pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:19996235pubmed:publicationTypeCase Reportslld:pubmed